Jane N. Winter, MD

Research Program

• Translational Research in Malignancy (TRIM)

Email

j-winter( at )northwestern.edu

Cancer-Focused Research

Winter's clinical and research interests focus on the malignant lymphomas (both Hodgkin and non-Hodgkin), particularly the development of novel therapies and the investigation of clinical and biologic correlates of prognosis. Dr. Winter has led investigator initiated trials, cooperative group clinical trials and pharmaceutical trials of novel agents including phase I and II trials of growth factors, vaccines, monoclonal antibodies, radioimmunotherapy, checkpoint inhibitors and other biologics and targeted agents. Currently, she is the principal investigator for clinical trials combining checkpoint inhibition with conventional chemotherapy for patients with newly diagnosed and relapsed/refractory Hodgkin Lymphoma. For more than three decades, Dr. Winter's research focused on developing reagents, biomarkers, and clinical indices for determining prognosis in the diffuse, large B-cell lymphomas. Despite efforts by many investigators to identify biologic markers of prognosis, clinical features remain the most powerful determinants of outcome. With one of her fellows, Dr. Frank (Zheng) Zhou, she developed a modern “enhanced” prognostic index for patients with DLBCL. This index, the NCCN-IPI, has the capacity to identify patients who have less than a 50% chance of surviving five years, and has now supplanted the IPI as the clinical tool to be used in predicting outcome for newly diagnosed patients with DLBCL. Dr. Winter continues to investigate biologic predictors of prognosis in DLBCL in collaboration with an international consortium of investigators. Dr. Winter is a Councilor and member of the Executive Committee for the American Society of Hematology, and a member of the NCI’s Lymphoma Steering Committee. Dr. Winter is a long-standing member of the Lymphoma Steering Committee for the Eastern Cooperative Oncology Group and its previous co-chair. She served a six year term as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine and has been a member of the National Comprehensive Cancer Network Hodgkin Lymphoma Guidelines Committee since its inception. She is currently a member of the NHLBI’s Data-Safety Monitoring Board for the BMT-CTN